A Case of Eosinophilic Colitis after BNT162b2 mRNA COVID-19 Vaccination
Journal of Interdisciplinary Medicine
; 7(2):44-46, 2022.
Article
in English
| EMBASE | ID: covidwho-2065359
ABSTRACT
Background:
BNT162b2 is a widely used mRNA COVID-19 vaccine for which 8.2% of participants above the age of 56 years have reported diarrhea as an adverse event. This case report highlights the possibility of eosinophilic colitis in post-vaccination diarrhea. Case report A 72-year-old male patient presented with generalized colicky abdominal pain and acute diarrhea after receiving the first dose of the BNT162b2 vaccine. Laboratory examination revealed peripheral blood eosinophilia with cecal and ascending colon mucosal eosinophilia with 100-130 cells/HPF and eosinophilic cryptitis. The patient's symptoms and eosinophilia resolved spontaneously and did not recur after the second dose of vaccination. More research is needed to confirm eosinophilic colitis as a possible vaccine adverse reaction. Copyright © 2022 Selva Yuwaraj Vadioaloo et al., published by Sciendo.
COVID-19 vaccine; eosinophilic colitis; vaccine adverse reactions; acute diarrhea; aged; article; ascending colon; case report; clinical article; colic; coronavirus disease 2019; drug therapy; eosinophil; eosinophilia; human; human cell; laboratory test; male; side effect; vaccination; messenger RNA; tozinameran
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Journal of Interdisciplinary Medicine
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS